Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Aug 11;19:187. doi: 10.1186/s13075-017-1397-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2017

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 2 — Therapeutic effects of Bz and Cyc on cellular subsets of 14-week-old and 22-week-old MRL/lpr mice. MRL/lpr mice aged 14 weeks were injected subcutaneously with Bz (750 μg/kg, twice weekly) or intraperitoneally with Cyc (1 mg/body weight, once in 2 weeks). At 22 weeks of age, mice were sacrificed and analyzed. a Weight of spleens and axillary lymph nodes. b Representative data for flow-cytometric analysis of splenic plasma cells (IgL-κ⁺CD138⁺) and T-cell subsets among Thy1.2⁺ T cells in Bz-treated or Cyc-treated mice. c Absolute numbers of each cellular subset in spleens. Values expressed as median with quartile range. Statistical analysis performed using one-way ANOVA analyses with Turkey post-hoc test. Bz bortezomib, Con control, Cyc cyclophosphamide